Liver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkey^a

References

• Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63(6):679–85.
   PubMedGoogle Scholar
• Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 2004;34(1):83–9.
   PubMedGoogle Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: Extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006;14(3):152–64.
   PubMedGoogle Scholar
• Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, . Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4): 572–8.
   PubMedGoogle Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45(7): 771–91.
   PubMedGoogle Scholar
• Fleischhaker C, Heiser P, Hennighausen K, Herpertz- Dahlmann B, Holtkamp K, Mehler-Wex C, . Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Trans 2007;114(2):273–80.
   PubMedGoogle Scholar
• Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, . Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 2009;19(5):563–73.
   PubMedGoogle Scholar
• Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, : Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41: 337–43.
   PubMed Web of Science ®Google Scholar
• Panagiotopoulos C, Ronsley R, Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry 2009;54(11):743–9.
   PubMedGoogle Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during firsttime use in children and adolescents. J Am Med Assoc 2009;302(16):1765–73.
   PubMed Web of Science ®Google Scholar
• Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002;41(12): 1439–46.
   PubMedGoogle Scholar
• Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatr 2003;42(10):1227–33.
   PubMedGoogle Scholar
• Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz, L, . Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treat treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatr 2008;165(11):1420–31.
   PubMed Web of Science ®Google Scholar
• Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010;19(2): 124–37.
   PubMedGoogle Scholar
• Erdogan A, Karaman MG, Ozdemir E, Yurteri N, Tufan AE, Kurcer MA. Six months of treatment with risperidone may be associated with non-significant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. J Child Adolesc Psychopharmacology 2010;20(5):407–13.
   PubMedGoogle Scholar
• Malone RP, Maıslın G, Choudhury MS, Gıfford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002;41(2): 140–7.
   PubMedGoogle Scholar
• Zuddas A, Di Martino A, Muglia P, Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000;10(2):79–90.
   PubMedGoogle Scholar
• Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002;110:e34.
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, . Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634–41.
   PubMed Web of Science ®Google Scholar
• Erdogan A, Atasoy N, Akkurt H, Ozturk D, Karaahmet E, Yalug I, . Risperidone and liver function tests in children and adolescents: A short-term prospective study. Progress NeuroPsychopharmacol Biol Psychiatr 2008; 32(3):849–57.
   PubMedGoogle Scholar
• Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, . Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol 2005;20(3):173–6.
   PubMedGoogle Scholar
• Garcia-Unzueta MT, Herran A, Sierra-Biddle D, Amado JA, Vazquez-Barquero JL, Alvarez C. Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal 2003;17(6):216–8.
   PubMedGoogle Scholar
• Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36(5): 701–5.
   PubMedGoogle Scholar
• Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 1999;9(2):93–8.
   PubMedGoogle Scholar
• Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007;68(Suppl 8):26–34.
   PubMedGoogle Scholar